Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Coley Pharmaceutical Group is a private company that was founded in 1997 to discover, develop and commercialise drugs based on CpG oligonucleotides (oligos). Since then, Coley scientists and their colleagues have continued to identify novel CpG oligos, as well as to develop an understanding of how these molecules work as they interact with the human immune system.

Because of their immunostimulatory properties, Coley believes that its CpG oligo product candidates have the potential to significantly enhance or supplant current more toxic and less effective cancer treatments, as well as improve the effects of newer immunotherapies. As shown in its preclinical studies, Coley's CpG oligo product candidates can stimulate the immune system to recognise and destroy cancer cells through selective killing mechanisms. Coley is developing its CpG oligos as monotherapies and for use in combination with existing treatments, including anticancer MAbs and other multi-drug regimens.

Coley focuses its internal product development efforts on cancer and on selected infectious diseases, and collaborates with partners for development of products in other infectious diseases, respiratory diseases and cancer vaccines. Coley has research and development operations in Langenfeld, Germany and Ottawa, Canada.